Beigene (Beijing) Biotechnology
Beigene (Beijing) Biotechnology is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Sponsor Oncomatryx Biopharma S.L.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Beigene (Beijing) Biotechnology?
The 2026-10-09 snapshot links Beigene (Beijing) Biotechnology to 3 distinct CTIS trials. Recorded services include Laboratory services, PD testing, tislelizumab supplier. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Beigene (Beijing) Biotechnology?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Beigene (Beijing) Biotechnology conducted?
The linked trials record locations in 9 countries, including Spain, France, Italy, Czechia, Germany. These are trial locations, not confirmed office locations or countries where Beigene (Beijing) Biotechnology delivered services.
What can this page tell me about Beigene (Beijing) Biotechnology's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Beigene (Beijing) Biotechnology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Beigene (Beijing) Biotechnology Co. Ltd.